Aptamer-Based Reagents

Simple SummaryContent extracted from patent full text and abstract with AI.

This invention describes aptamer-based reagents that can specifically bind to molecules involved in blood coagulation (hemostasis). The aptamers are modified with photo-unstable (photolabile) protective groups and specialized linkers, allowing for covalent attachment to target molecules. Upon exposure to specific wavelengths of light (UV or infrared), these protective groups are removed, leading to controlled activation or release of the target molecule at a desired location and time in the body. This technology enables precise, localized modulation (activation or inhibition) of blood coagulation processes, potentially offering new treatment approaches for disorders related to abnormal bleeding or clotting.

Use CasesContent extracted from patent full text and abstract with AI.

• Targeted local activation of blood clotting in surgery to stop bleeding, especially in difficult-to-access tissues or during minimally invasive procedures.
• Treatment of bleeding disorders or perioperative/postoperative bleeding by precise local release of coagulation activators.
• Selective embolization (blocking) of tumor-feeding blood vessels in cancer therapy to starve tumors of blood supply with minimal collateral damage.
• Localized induction of blood clotting in vascular malformations or aneurysms to prevent rupture.
• Thrombus-selective fibrinolysis (clot breakdown) to treat thromboembolic diseases with reduced bleeding risk compared to systemic treatments.
• Controlled treatment of varicose veins by photoinduced coagulation restricted to diseased vessels.

BenefitsContent extracted from patent full text and abstract with AI.

• Highly specific and controllable activation or inhibition of blood coagulation, reducing the risk of systemic side effects.
• Minimally invasive, as activation can be performed non-invasively with light at the target site—no need for surgery or systemic drug administration.
• Reduced toxicity and side effects due to minimal off-target release of active molecules.
• Ability to deliver and activate therapeutic agents only where needed, sparing healthy tissues and reducing treatment complications.
• Potential for use in a broad range of medical scenarios, from emergency bleeding control to highly selective cancer therapy or treatment of vascular diseases.
• Enables new modes of drug delivery and activation based on light, offering spatial and temporal precision in therapeutic interventions.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The invention relates to an aptamer-based reagent, comprising at least one target molecule that is involved in hemostasis with an aptamer binding through procoagulatory, proaggregatory and/or profibrinolytic activity, wherein at least one base of the aptamer has at least one photo-unstable protective group, and at least one linker at the 5' end, 3' end, on one of the nucleobases and/or on the ribose phosphate backbone of the aptamer. The linker has at least one further photo-unstable protective group and at least one leaving group, for the production of a covalent link to the target molecule, and aptamer target molecule complexes, which are obtained from the reaction of the aptamer-based reagent with a target molecule, wherein a covalent bond between the aptamer-based reagent and the target molecule can be formed while cleaving the leaving group for the production of a covalent link to the target molecule.